Advertisement

Case V: 3DMed: Digital Technology—Navigating Precision Medicine Towards Success

  • Xiaoming ZhuEmail author
Chapter
First Online:
  • 1k Downloads
Part of the Management for Professionals book series (MANAGPROF)

Abstract

In early 2015, the U.S. proposed the Precision Medicine Initiative (PMI). Almost at the same time, the Chinese government began increasing investment into the precision medicine field, which was officially included in China’s 13th Five-Year Plan at the end of 2016. Precision medicine soon evolved from being an academic concept into an economic buzzword attracting global attention. Estimates predict that from 2015 to 2022, the Compound Annual Growth Rate (CAGR) for the global precision medicine market will be 12.60%, reaching over USD 88 billion by 2022. The precision medicine market is now more promising than ever.

This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

This case study was co-authored by Professor Zhu Xiaoming, Part-time Case Writer Song Yanbo, and Research Assistant Huang Chengyan and Jin Lijia of China Europe International Business School. It was written with the support of the 3D Medicines Corporation.

References

  1. The White House. Fact Sheet: President Obama’s Precision Medicine Initiative[R]. Washington D. C.: The White House, 2015.Google Scholar
  2. State Council of the People’s Republic of China. Notice of National Development Planning for Strategic Emerging Industries in the 13th Five-Year Plan[R]. Beijing: State Council of the People’s Republic of China, 2016.Google Scholar
  3. BIS Research. Research and Markets: Global Precision Medicine Market — Estimates and Forecasts Through 2015—2022[R]. Business Wire, 2015.Google Scholar
  4. ZHU P. Competition among Genetic Testing Institutions Has Intensified and the Lack of Pathologists Must be Addressed[N]. 21st Century Business Herald, 2017-01-12.Google Scholar
  5. NIH. The Precision Medicine Initiative[EB/OL]. [2017-03-18]. https://syndication.nih.gov/multimedia/pmi/infographics/pmi-infographic.
  6. CUI X. China to Launch a Precision Medicine Plan with RMB 60 Billion of Investment by 2030 [J]. China Economic Weekly, 2015-10-12.Google Scholar
  7. SUN A. Is Precision Medicine a Bubble or a Great Opportunity?[J]. Caijing Magazine, 2016-11-28.Google Scholar
  8. QIN X. Simon Xiong of 3DMed Wants to Provide Precision Medicine for Cancer Diagnosis and Treatment from A-Z[J]. China Business News, 2015-11-13.Google Scholar
  9. ZHENG Q. Four Areas 3DMed Will Focus on after Closing RMB 146 Million of Financing [EB/OL]. (2015-12-16). http://vcbeat.net/25092.
  10. Anonymity. Tasly Enters the Anti-cancer Precision Medicine Market through Collaboration with 3DMed[EB/OL]. (2015-11-16). http://www.360zhyx.com/home-search-index-rid-62786.shtml.
  11. ZUO L. Authoritative International Journal on Digestion Publishes Progress Updates on Research by 3DMed and Chinese Scholars into How Tumour Heterogeneity Affects Medicine Therapy[R]. www.seq.cn, 2016.
  12. JOLIE A. My Medical Choice[J]. New York Times, 2013-05-14.Google Scholar
  13. WANG Y. Price Competition in DNA Sequencing: A Drop from RMB 80,000 to 10,000 in Two Years[N]. China Business News, 2015-09-02.Google Scholar
  14. XIAO M. Chen Yingjie in Da’an Gene: Early Price Competition in the Chinese Market, Da’an to Focus on Follow-up Services[N]. 21st Century Business Herald, 2016-01-08.Google Scholar
  15. WANG Y. Price Competition in DNA Sequencing: A Drop from RMB 80,000 to 10,000 in Two Years[N]. China Business News, 2015-09-02.Google Scholar
  16. World Health Organisation. Cancer Fact Sheet: Breast Cancer[R/OL]. [2017-03-18]. http:// gco.iarc.fr/today/fact-sheets-cancers?cancer = 15&type = 0&sex = 2.Google Scholar
  17. CHEN W, et al. Cancer statistics in China, 2015[J]. A Cancer Journal for Clinicians, 2016-01-25.Google Scholar
  18. DUNCAN J A, REEVES J R, COOKE T G. BRCA1 and BRCA2 proteins: roles in health and disease[J]. Molecular Pathology, 1998, 51 (5): 237–247.CrossRefGoogle Scholar
  19. NORDQVIST C. Breast Cancer: Causes, Symptoms and Treatments[J]. Medical News Today, 2016-05-05.Google Scholar
  20. Anonymity. Women’s Cancer Prevention Fund Aims to Care for Groups at High Risk of Breast Cancer[EB/OL]. (2015-10-21). http://www.sohu.com/a/36988492_268116.
  21. American Cancer Society, “Breast Cancer Prevention and Early Detection 2015”, Accessed at https://old.cancer.org/acs/groups/cid/documents/webcontent/003165-pdf.pdf on March 18, 2017.
  23. Women’s Cancer Prevention Fund Aims to Care for Groups at High Risk of Breast Cancer[EB/OL]. (2015-10-21). http://www.sohu.com/a/36988492_268116.
  24. HOWARD J. Minimum Latency & Types or Categories of Cancer[J]. World Trade Centre Health Program, 2012-10-17.Google Scholar
  25. GORSKI D. The early detection of cancer and improved survival: more complicated than most people think[J]. Science-Based Medicine, 2008-05-12.Google Scholar
  26. CARLO M, CROCE M D. Oncogenes and Cancer[J]. The New England Journal of Medicine, 2008, 358 (5): 502–511.CrossRefGoogle Scholar
  27. ZONG C, et al. Genome-Wide Detection of Single-Nucleotide and Copy-Number Variations of a Single Human Cell[J]. Science, 2012, 338: 1622–1626.CrossRefGoogle Scholar
  28. REGALADO A. What Are Liquid Biopsies Useful for[N]. MIT Technology Review, 2015-08-13.Google Scholar
  29. LI Y. Increase in Anti-cancer Precision Medicine[N]. Medicine Economic News, 2015-12-14.Google Scholar
  30. PRASAD V. Perspective: The Precision-oncology Illusion[J]. Nature, 2016-09-07.Google Scholar
  31. Hsmap. 20 CFDA-approved Anti-cancer Targeted Drugs and Their Market[EB/OL]. (2017-02-20). http://med.sina.com/article_detail_103_2_20589.html.
  32. GAO Q, et al. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents[J]. Gastroenterology, 2016-09-24.Google Scholar
  33. Anonymity, An Interview with 3DMed’s Joint CEO John Gong: Have You Grasped the Opportunity of the Revolution in R&D for New Drug?[EB/OL]. (2014-12-09). http://www.360zhyx.com/home-research-index-rid-32965.shtml.
  34. SZNOL M, CHEN L. Antagonist antibodies to PD–1 and B7–H1 (PD–L1) in the treatment of advanced human cancer[J]. Clinical Cancer Research, 2013, 19: 1021–1034.CrossRefGoogle Scholar
  35. COUZIN-FRANKEL J. Breakthrough of the year 2013. Cancer immuno-therapy[J]. Science, 2013, 342(6165): 1432–1433.CrossRefGoogle Scholar
  36. RAEDLER L A. Tecentriq (Atezolizumab) First PD–L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma, American Health & Drug Benefits, October 6, 2016.Google Scholar
  37. TORRE L A, et al. Global cancer statistics 2012[J]. A Cancer Journal for Clinicians, 2015, 65(2): 87–108.Google Scholar
  38. CHEN W, et al. Cancer statistics in China, 2015[J]. A Cancer Journal for Clinicians, 2016-01-25.Google Scholar
  39. MO R. Has a Winter of Investment and Financing Come to the Healthcare Industry? The Cancer Sector is Still Hot![R].VCBeat Research, 2016-10-12.Google Scholar
  40. REN Z. 51job’s Survey Report Shows a Sharp Acceleration in Employee Turnover and Increased Caution among Companies Towards Salary Adjustment[N]. China Labour and Social Security News, 2016-12-30.Google Scholar

Copyright information

© Shanghai Jiao Tong University Press and Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.China Europe International Business SchoolShanghaiChina

Personalised recommendations

Cite chapter

Buy options